NasdaqGM:OCSPharmaceuticals
Oculis FDA Milestone And DME Data Spotlight Eye Pipeline And Valuation
Oculis Holding secured a formal Special Protocol Assessment from the FDA for its pivotal Phase 3 PIONEER-1 trial of Privosegtor in optic neuritis.
The FDA agreement confirms that the PIONEER-1 trial design is adequate to support a potential future NDA submission.
In parallel, new findings from the DME AWARE study support further development of OCS-01 eye drops for diabetic macular edema.
These updates arrive with NasdaqGM:OCS trading at $31.09, with the stock up 13.1% over the past week and...